REVELUTION Trial (NCT 05320406) comparing Relugolix versus Leuprolide in combination with XRT. Short-term HRQOL outcomes presented at ASCO GU. Primary endpoint of CV toxicity, coronary plaque development pending. #GU24 @PfizerOncMed @SumitomoPharma
🇺🇸REVELUTION trial: XRT + (reluoglix vs leuprolide) for localized PCa (n=65)
🔷Primary outcome of coronary plaque change on cardiac CT at 12 months post-Rx: pending (late 2024)
📌Superior short-term IPSS scores with relugolix (faster T supp --> prostate downsizing & ⬇️ obstructive uropathy?)
📌94% of pts preferred relugolix if given choice (assuming equal cost...)
@urotoday #GU24View quoted post on X
